Elanco Animal Health Incorporated Deferred Income Tax Expense (Benefit)
Elanco Animal Health Incorporated (ELAN) reported Deferred Income Tax Expense (Benefit) of -$134.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-24
- Elanco Animal Health Incorporated deferred income tax expense (benefit) for the quarter ending 2023-03-31 was $2.00M.
- Elanco Animal Health Incorporated deferred income tax expense (benefit) for the quarter ending 2022-12-31 was -$29.00M.
- Elanco Animal Health Incorporated deferred income tax expense (benefit) for the quarter ending 2022-09-30 was $6.00M.
- Elanco Animal Health Incorporated deferred income tax expense (benefit) for the quarter ending 2022-06-30 was -$27.00M.
- Elanco Animal Health Incorporated deferred income tax expense (benefit) for fiscal 2025 was -$134.00M.
- Elanco Animal Health Incorporated deferred income tax expense (benefit) for fiscal 2024 was -$112.00M.
- Elanco Animal Health Incorporated deferred income tax expense (benefit) for fiscal 2023 was -$80.00M.
- Elanco Animal Health Incorporated deferred income tax expense (benefit) for fiscal 2022 was -$57.00M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 3 month as first filed | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 6 month as first filed | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 9 month as first filed | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$134.00M 10-K · filed 2026-02-24 | |||||||
| 2024-12-31 | -$112.00M 10-K · filed 2026-02-24 | |||||||
| 2023-12-31 | -$80.00M 10-K · filed 2026-02-24 | |||||||
| 2023-03-31 | $2.00M 10-Q · filed 2023-05-09 | -$27.00M derived: sum of 2 quarters · filed 2025-02-25 | -$21.00M derived: sum of 3 quarters · filed 2025-02-25 | -$48.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | -$29.00M derived: 10-K 12 month − 10-K 9 month · filed 2025-02-25 | -$23.00M derived: sum of 2 quarters · filed 2025-02-25 | -$50.00M derived: sum of 3 quarters · filed 2025-02-25 | -$57.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $6.00M derived: 10-K 9 month − 10-K 6 month · filed 2023-03-01 | -$21.00M derived: sum of 2 quarters · filed 2023-03-01 | -$28.00M 10-K · filed 2023-03-01 | -$36.00M 10-Q · filed 2022-11-08 | -$54.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-06-30 | -$27.00M derived: 10-K 6 month − 10-Q 3 month · filed 2023-03-01 | -$34.00M 10-K · filed 2023-03-01 | -$40.00M 10-Q · filed 2022-08-08 | -$60.00M derived: sum of 3 quarters · filed 2024-02-26 | -$62.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-03-31 | -$7.00M 10-Q · filed 2023-05-09 | -$11.00M 10-Q · filed 2022-05-09 | -$33.00M derived: sum of 2 quarters · filed 2024-02-26 | -$35.00M derived: sum of 3 quarters · filed 2024-02-26 | -$127.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2021-12-31 | -$26.00M derived: 10-K 12 month − 10-K 9 month · filed 2024-02-26 | -$28.00M derived: sum of 2 quarters · filed 2024-02-26 | -$120.00M derived: sum of 3 quarters · filed 2024-02-26 | -$148.00M 10-K · filed 2024-02-26 | -$154.00M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | -$2.00M derived: 10-K 9 month − 10-K 6 month · filed 2023-03-01 | -$94.00M derived: sum of 2 quarters · filed 2023-03-01 | -$122.00M 10-K · filed 2023-03-01 | -$119.00M 10-Q · filed 2021-11-05 | -$76.00M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | -$92.00M derived: 10-K 6 month − 10-K 3 month · filed 2023-03-01 | -$120.00M 10-K · filed 2023-03-01 | -$114.00M 10-Q · filed 2021-08-09 | -$74.00M derived: sum of 3 quarters · filed 2023-03-01 | -$156.00M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | -$28.00M 10-K · filed 2023-03-01 | -$32.00M 10-Q · filed 2021-05-07 | $18.00M derived: sum of 2 quarters · filed 2023-03-01 | -$64.00M derived: sum of 3 quarters · filed 2023-03-01 | -$117.00M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $46.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$36.00M derived: sum of 2 quarters · filed 2023-03-01 | -$89.00M derived: sum of 3 quarters · filed 2023-03-01 | -$114.00M 10-K · filed 2023-03-01 | -$124.80M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$82.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$135.00M derived: sum of 2 quarters · filed 2021-11-05 | -$160.00M 10-Q · filed 2021-11-05 | -$159.80M 10-Q · filed 2020-11-06 | -$174.90M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | -$53.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$78.00M 10-Q · filed 2021-08-09 | -$78.40M 10-Q · filed 2020-07-30 | -$92.90M derived: sum of 3 quarters · filed 2022-02-28 | -$118.30M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | -$25.00M 10-Q · filed 2021-05-07 | -$25.10M 10-Q · filed 2020-05-07 | -$39.90M derived: sum of 2 quarters · filed 2022-02-28 | -$65.30M derived: sum of 3 quarters · filed 2022-02-28 | -$41.30M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | -$14.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$40.30M derived: sum of 2 quarters · filed 2022-02-28 | -$16.30M derived: sum of 3 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | $100.00K 10-K · filed 2020-02-28 | |||
| 2019-09-30 | -$25.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$1.40M derived: sum of 2 quarters · filed 2020-11-06 | $14.90M 10-Q · filed 2020-11-06 | -$58.40M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $24.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $40.30M 10-Q · filed 2020-07-30 | -$33.00M derived: sum of 3 quarters · filed 2021-03-01 | -$31.20M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $16.30M 10-Q · filed 2020-05-07 | -$57.00M derived: sum of 2 quarters · filed 2021-03-01 | -$55.20M derived: sum of 3 quarters · filed 2021-03-01 | -$42.00M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | -$73.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$71.50M derived: sum of 2 quarters · filed 2021-03-01 | -$58.30M derived: sum of 3 quarters · filed 2021-03-01 | -$60.70M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $15.00M derived: sum of 2 quarters · filed 2019-11-08 | $12.60M 10-Q · filed 2019-11-08 | $6.20M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $13.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $10.80M 10-Q · filed 2019-08-13 | $4.40M derived: sum of 3 quarters · filed 2020-02-28 | |||||
| 2018-03-31 | -$2.40M 10-Q · filed 2019-05-14 | -$8.80M derived: sum of 2 quarters · filed 2020-02-28 | ||||||
| 2017-12-31 | -$6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$13.40M 10-K · filed 2020-02-28 | ||||||
| 2017-09-30 | -$7.00M 10-Q · filed 2018-11-08 | |||||||
| 2016-12-31 | -$5.90M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |